Clarity confirms no supply interruptions to its ongoing clinical trials programs
Sydney, Australia 2 March 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, notes the recent supply interruption for Novartis’ Pluvicto™ radiotherapy to patients1-2 and confirms Clarity’s Targeted Copper Theranostics (TCTs) products and clinical development programs are…